- Home
- Publications
- Publication Search
- Publication Details
Title
New biologics for allergic diseases
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 14, Issue 4, Pages 285-296
Publisher
Informa UK Limited
Online
2018-04-03
DOI
10.1080/1744666x.2018.1459188
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biologics and biomarkers for asthma, urticaria, and nasal polyposis
- (2017) Thomas B. Casale JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
- (2017) Peter G Gibson et al. LANCET
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- (2017) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe and Difficult-to-Treat Asthma in Adults
- (2017) Elliot Israel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tezepelumab in Adults with Uncontrolled Asthma
- (2017) Jonathan Corren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
- (2017) Guy Brusselle et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
- (2017) Anna Maria Riccio et al. Clinical and Translational Allergy
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
- (2016) Claus Bachert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biomarkers in asthmatic patients: Has their time come to direct treatment?
- (2016) Alalia Berry et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
- (2016) Sherif Gonem et al. Lancet Respiratory Medicine
- Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
- (2016) Nicola A Hanania et al. Lancet Respiratory Medicine
- Past, present, and future for biologic intervention in atopic dermatitis
- (2015) M. D. Howell et al. ALLERGY
- Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care
- (2015) Merritt L. Fajt et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The prevalence of severe refractory asthma
- (2015) Pieter-Paul W. Hekking et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Eosinophilic Esophagitis
- (2015) Glenn T. Furuta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
- (2015) Christopher E Brightling et al. Lancet Respiratory Medicine
- Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
- (2014) Gail M. Gauvreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
- (2014) Lisa A. Beck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
- (2014) Oliver Kornmann et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Asthma: pathogenesis and novel drugs for treatment
- (2014) J. T. Olin et al. BMJ-British Medical Journal
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
- (2014) Mario Castro et al. Lancet Respiratory Medicine
- Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines
- (2013) M. Hotze et al. ALLERGY
- Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
- (2013) William W. Busse et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Exploring the Effects of Omalizumab in Allergic Asthma
- (2013) Nicola A. Hanania et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
- (2013) Nicola A. Hanania et al. ANNALS OF INTERNAL MEDICINE
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- New era of biologic therapeutics in atopic dermatitis
- (2013) Emma Guttman-Yassky et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma
- (2013) Michael E. Wechsler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
- (2013) Allen Kaplan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
- (2013) Marcus Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
- (2013) Sally Wenzel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial
- (2012) P. Nair et al. CLINICAL AND EXPERIMENTAL ALLERGY
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
- (2012) Edward Piper et al. EUROPEAN RESPIRATORY JOURNAL
- Th2 cytokine antagonists: potential treatments for severe asthma
- (2012) Philip M Hansbro et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
- (2012) Philippe Gevaert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
- (2012) Huib A.M. Kerstjens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reslizumab for Poorly Controlled, Eosinophilic Asthma
- (2011) Mario Castro et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
- (2011) Philippe Gevaert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial
- (2011) Jonathan M. Spergel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
- (2009) A Straumann et al. GUT
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
- (2009) Pranabashis Haldar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
- (2009) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started